Aim: The purpose of this study is to evaluate the efficacy of Remdesivir in patients with covid 19. Materials and methods: The division of respiratory medicine was responsible for carrying out this investigation. This research included both male and female participants with COVID-19 who were at least 18 years old, had an RT-PCR test that was positive for SARS-CoV-2, and either had pneumonia that was verified by chest imaging or had an oxygen saturation of 94%. The cases were separated into two groups: Group A consisted of cases of Covid 19 respiratory infection that were treated with Remdesivir therapy in addition to the standard care (n=50), and Group B consisted of cases of Covid 19 respiratory infection that were treated with the standard care but did not receive Remdesivir (n=50). Results: The majority of patients (36 out of 50) in Group A who were recruited in the trial were eventually released. This is a 72% success rate. 14 (or 28%) of the patients ultimately passed away as a result of their condition. In Group A, there was a death rate of 28 percent. The majority of the patients who passed away were those with severe illness (78.57%), whereas just 21.43% of the patients had intermediate disease. There were a total of 50 patients who were not given remdesivir, and of them, 9 passed away. The individuals who did not get remdesivir had an 18% higher risk of passing away. Conclusion: It is very unlikely that therapy with an antiviral medicine alone, such as Remdesivir, would be adequate for COVID-19 patients given the significant death rate that was seen in the current trial despite the use of Remdesivir.